QQ客服 官方微博 反馈留言

	Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
	Mu, Yuxin; Hao, Xuezhi; Yang, Ke; Ma, Di; Wang, Shouzheng; Xu, Ziyi; Li, Junling; Xing, Puyuan
	2019
卷号	14期号:3页码:335-342
ISSN号	1776-2596
DOI	10.1007/s11523-019-00644-6
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6340696
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Mu, Yuxin,Hao, Xuezhi,Yang, Ke,et al. Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib[J],2019,14(3):335-342.
APA	Mu, Yuxin.,Hao, Xuezhi.,Yang, Ke.,Ma, Di.,Wang, Shouzheng.,...&Xing, Puyuan.(2019).Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.,14(3),335-342.
MLA	Mu, Yuxin,et al."Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib".14.3(2019):335-342.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。